[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"radiation\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:radiation":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,13,0,[8,41,63,86,104,128,153,185,213,236,260,295,321],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100645091","phase-2-gcc-2545--improving-post-radiotherapy-respiratory-function-through-sparing-serial-and-parallel-components-in-the-lung-100645091",false,"NCT07679607","GCC 2545- Improving Post-Radiotherapy Respiratory Function Through Sparing Serial and Parallel Components in the Lung","INSPIRE","Inclusion Criteria:\n\n* Step 1- Inclusion Criteria\n\n  1. Adult (≥18 years) patients (both sexes) with histologically diagnosed Stage III NSCLC per AJCC ver 9\n  2. Patients to be treated with definitive external beam photon radiotherapy with or without systemic therapy (e.g., chemothrapy, immunotherapy).\n  3. No restrictions on number radiotherapy fractions, or location\u002Fnumber of lesions\n  4. ECOG performance status ≤ 3\n  5. Ability to hold breath for ≥ 15 seconds\n  6. Patient has signed informed consent document and agreed to study procedures\n\nStep 2- Inclusion Criteria 1. Patient has completed 4DCT and BHCT with subsequent plans created and Radiation Oncologist has determined that patient would benefit from INSPIRE RT.\n\nExclusion Criteria:\n\n* Step 1- Exclusion Criteria\n\n  1. Prior lung cancer-directed radiotherapy\n  2. Recent (\\\u003C 12 mo) or planned lung surgery (which would confound pre- and post-RT lung function measures)\n  3. Patients with metal implants or metal stents in the thoracic region\n  4. Known severe chronic obstructive pulmonary disease or interstitial lung disease\n  5. Women who are pregnant or trying to get pregnant\n\nStep 2- Exclusion Criteria\n\n1\\. Patient found to not benefit from INSPIRE RT after comparison of treatment plans.","ALL","18 Years",{"count":19,"type":20},70,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","Decreased respiratory function is a common side effect experienced by non-small cell lung cancer (NSCLC) patients who receive radiation therapy. In current clinical practice when treating cancerous lesions in the lung, it is not standard to explicitly try and avoid excessive radiation dose and therefore radiation injury to smaller airways. However, because of this patients may obtain damage to an airway segment can cause downstream regions in the lung to lose their \"supply line\" and, therefore, cause patients to lose the ability to exchange oxygen with the blood. The purpose of this clinical trial is to systematically compare post-treatment lung function of those who receive regular clinical radiation therapy (standard of care \\[SoC\\]) versus those who receive the airway-sparing radiation therapy regimen. The investigators hope to show that, by preserving airways and connected lung regions, participants will be able to retain a larger amount of their lung function, which will have a direct, positive impact on their post-treatment quality of life.",[26,27],"Lung Cancer (NSCLC)","Radiation","NOT_YET_RECRUITING","2026-06-29",{"date":31,"type":32},"2026-07-01","ACTUAL",{"date":34,"type":20},"2026-08",{"date":36,"type":20},"2030-08",{"name":38,"class":39},"University of Maryland, Baltimore","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":48,"targetDuration":4,"studyType":21,"phases":50,"briefSummary":52,"conditions":53,"keywords":4,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":40},"100623559","gcc-2546--motion-management-100623559","NCT07398209","GCC 2546- Motion Management","Combining 4D MRI and 4DCT for Personalized Volumetric Motion Monitoring in Lung Radiation Therapy","Inclusion Criteria:\n\n1. Adult (≥18 years) patients (both sexes) with histologically diagnosed Stage II-IIIb NSCLC\n2. Patients to be treated with definitive external beam photon radiotherapy with or without systemic therapy (e.g., chemotherapy, immunotherapy).\n3. No restrictions on number radiotherapy fractions, or location\u002Fnumber of lesions\n4. ECOG performance status ≤ 3\n5. Ability to undergo MRI scans\n6. Patient has signed informed consent document and agreed to study procedures\n\nExclusion Criteria:\n\n1. Pre-existing contraindications for MRI, such as any MRI-conditional or MRI-unsafe foreign objects within the body, non-removable ear cochlear or eye implant, aneurysm clip, cardiac pacemaker\u002Fwires, internal defibrillator, tissue expander, recent stent placement, penile prosthesis, medication patch, artificial limb, pregnancy, and claustrophobia\n2. Women who are pregnant or trying to get pregnant (self-reported)\n3. Pain in supine position or inability to raise arm above head in supine position",{"count":49,"type":20},44,[51],"NA","The purpose of this study is to assess a real time motion tracking of lung tumors and important organs next to the tumor while breathing during a participant's radiation treatment. This will be assessed through a four-dimensional magnetic resonance imaging (MRI) scan before starting your radiation treatment and x-ray fluoroscopy images that are taken during radiation",[26,27],"RECRUITING","2026-06-23",{"date":57,"type":32},"2026-06-26",{"date":59,"type":32},"2026-04-14",{"date":61,"type":20},"2029-04",{"name":38,"class":39},{"id":64,"slug":65,"hasResults":11,"nctId":66,"briefTitle":67,"officialTitle":67,"acronym":4,"eligibilityCriteria":68,"healthyVolunteers":11,"sex":16,"minAge":69,"maxAge":70,"enrollmentInfo":71,"targetDuration":4,"studyType":73,"phases":4,"briefSummary":74,"conditions":75,"keywords":4,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":40},"100637665","baseline-anxiety-trajectories-in-pediatric-radiation-therapy-observational-cohort-100637665","NCT07575815","Baseline Anxiety Trajectories in Pediatric Radiation Therapy Observational Cohort","Inclusion Criteria:\n\nTo be eligible to participate in this study, an individual must meet all of the following criteria:\n\n* Provision of signed and dated informed consent from a parent or legal guardian.\n* For children age 7 and older, provision of informed assent in addition to parental consent, consistent with institutional guidelines.\n* Stated willingness of parent\u002Fguardian and child (as appropriate) to comply with study procedures (i.e., observation during scheduled radiation therapy appointments).\n* Male or female, ages 2-12 years.\n* Scheduled to undergo radiation therapy at MD Anderson Cancer Center.\n\nExclusion Criteria:\n\nAn individual who meets any of the following criteria will be excluded from participation in this study:\n\n* Has already completed the simulation session for radiation therapy prior to enrollment.\n* Declines parental consent or, when applicable, child assent.","2 Years","12 Years",{"count":72,"type":20},20,"OBSERVATIONAL","This is a prospective, observational cohort study of pediatric patients ages 2-12 undergoing radiation therapy at MD Anderson Cancer Center.",[76,27],"Anxiety","2026-05-08",{"date":79,"type":32},"2026-05-11",{"date":81,"type":32},"2026-05-06",{"date":83,"type":20},"2029-03-01",{"name":85,"class":39},"M.D. Anderson Cancer Center",{"id":87,"slug":88,"hasResults":11,"nctId":89,"briefTitle":90,"officialTitle":90,"acronym":4,"eligibilityCriteria":91,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":92,"targetDuration":4,"studyType":73,"phases":4,"briefSummary":94,"conditions":95,"keywords":4,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":40},"100538818","prospective-evaluation-of-the-relation-between-different-questionnaires-measuring-radiation-induced-side-effect-100538818","NCT06295783","Prospective Evaluation of the Relation Between Different Questionnaires Measuring Radiation-induced Side-effect","Inclusion Criteria:\n\n* Age ≥18 years\n* English as a primary language\n* Participants with a diagnosis of HNC undergoing active curative RT or having received curative RT within the past 5 years at MD Anderson\n* Ability to complete the survey(s) of their own volition\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years\n* Non-English speaking participants\n* Participants who are receiving or have received RT in a non-HN site.\n* Participants in follow up and over 5 years from post-treatment\n* Neurocognitive deficits that render patients unable to complete the survey(s) on their own.",{"count":93,"type":20},300,"To learn more about how you would rate the intensity or severity of your symptoms during or after radiation therapy using questionnaires with different rating scales.",[27],"2026-01-13",{"date":98,"type":32},"2026-01-14",{"date":100,"type":32},"2024-06-10",{"date":102,"type":20},"2027-02-01",{"name":85,"class":39},{"id":105,"slug":106,"hasResults":11,"nctId":107,"briefTitle":108,"officialTitle":108,"acronym":109,"eligibilityCriteria":110,"healthyVolunteers":11,"sex":111,"minAge":17,"maxAge":112,"enrollmentInfo":113,"targetDuration":4,"studyType":21,"phases":115,"briefSummary":116,"conditions":117,"keywords":4,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":40},"100367868","recurindex-guided-avoidance-of-regional-nodal-irradiation-for-node-positive-breast-cancer-100367868","NCT04069884","RecurIndex Guided Avoidance of Regional Nodal Irradiation for Node Positive Breast Cancer","RIGAIN","Inclusion Criteria:\n\n* Age ≥ 18 years old, ≤ 70 years old.\n* Eastern Cooperative Oncology Group (ECOG) ≤ 2.\n* Postoperative pathology is clearly diagnosed as invasive breast cancer.\n* Meet the clinical definition of low risk: ①Axillary lymph node micrometastasis (N1mic) or ②N1 patients who meet the following conditions at the same time, a）Age ≥ 40 years old, b）Vascular tumor thrombus (LVI) negative or allow few positive LVI (excluding extensive or massive LVI), c）Three subtypes are allowed (Lumina A, Lumina B\u002FHER2 negative, Lumina B\u002FHER2 positive) , namely ER positive (ER ≥ 1%), HER2 negative (HER2 expression negative or + by IHC, or 2+ but negative by FISH) or ER positive (ER ≥ 1%), HER2 positive (3+ by IHC, or 2+ but positive by FISH).\n* Postoperative pathological diagnosis of axillary lymph node status is any of the following: a. Sentinel lymph node biopsy or axillary lymph node dissection for micrometastasis (N1mic), b. Sentinel lymph node biopsy for 1-2 lymph node macrometastasis (N1sln), c. Sentinel lymph node biopsy + axillary lymph node dissection or simple axillary lymph node dissection for 1-3 lymph node metastasis (N1).\n* The primary tumor and breast undergo breast-conserving surgery or total resection ± breast reconstruction (autologous\u002Fprosthetic).\n* There must be adequate systemic examination (such as chest X-ray, B-ultrasound, CT, etc.) within 3 months before randomization of radiotherapy to confirm that there is no distant metastasis.\n* No contralateral breast cancer must be confirmed by molybdenum target and\u002For MRI within 12 months before randomization of radiotherapy.\n* At least 4 courses of adjuvant chemotherapy with anthracycline or taxane should be completed after surgery. If patients with HR positive, HER2 negative tumor underwent Multigene Assays, with low risk scores, omitting chemotherapy is permitted.\n* Radiotherapy must be performed sequentially after the completion of adjuvant chemotherapy, starting no later than 8 weeks after the end of chemotherapy.\n* The patient must have sufficient primary fresh frozen specimens or post-paraffin tissue sections for RecurIndex testing.\n* No previous history of malignant tumors, except for basal cell carcinoma of the skin.\n* Signed an informed consent form.\n\nExclusion Criteria:\n\n* Postoperative radiotherapy was confirmed as T3-4, N0, N2-3, M1 lesion staging before enrollment.\n* Receive any new adjuvant therapy before surgery, including chemotherapy, endocrine therapy, targeted therapy or radiation therapy.\n* Patients who underwent total mastectomy and only sentinel lymph node biopsy.\n* Have a history of contralateral breast cancer.\n* History of chest radiotherapy.\n* combined with severe heart, lung, liver, kidney, hematopoietic, neurological diseases, and mental illness.\n* History of autoimmune diseases such as scleroderma or active lupus erythematosus.\n* pregnant and lactating patients.","FEMALE","70 Years",{"count":114,"type":20},540,[51],"The purpose of this study is to validate whether clinically low-risk, and RecurIndex high-risk N1 patients receiving regional lymph node radiotherapy can further improve clinical outcomes.",[118,27],"Breast Cancer","2025-09-16",{"date":121,"type":32},"2025-09-22",{"date":123,"type":32},"2019-08-20",{"date":125,"type":20},"2030-12-31",{"name":127,"class":39},"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University",{"id":129,"slug":130,"hasResults":11,"nctId":131,"briefTitle":132,"officialTitle":133,"acronym":134,"eligibilityCriteria":135,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":136,"enrollmentInfo":137,"targetDuration":4,"studyType":21,"phases":139,"briefSummary":140,"conditions":141,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":144,"lastUpdatePostDateStruct":145,"startDateStruct":147,"completionDateStruct":149,"leadSponsor":151,"locationsCount":4},"100605453","phase-2-scrt-followed-by-ak112-in-pmmrmss-mid-low-rectal-cancer-100605453","NCT07162714","SCRT Followed by AK112 in pMMR\u002FMSS Mid-low Rectal Cancer","Short-Course Radiotherapy Followed by Ivonescimab (AK112) in pMMR\u002FMSS Mid-Low Rectal Cancer: An Exploratory Phase II Clinical Study.","STAR","Inclusion Criteria:\n\n1. Aged between 18 and 75 years old;\n2. Eastern Cooperative Oncology Group (ECOG) performance status score of 0 - 1;\n3. Histopathologically confirmed rectal adenocarcinoma, without any prior anti - tumor treatment; The status of MMR\u002FMSI is detected by IHC\u002FPCR in pathological biopsy to clarify that the patient's classification is pMMR\u002FMSS;\n4. The lower border of the lesion is ≤ 7 cm from the anal verge as determined by fibrocolonoscopy or digital rectal examination;\n5. Baseline magnetic resonance staging is cT2 - 4 and\u002For N+, excluding any of cT4b, N2, positive mesorectal fascia (MRF+), extramural venous invasion (EMVI+), lateral lymph node metastasis, and distant metastasis (according to the 8th edition of the AJCC Cancer Staging Manual);\n6. Able to accept the treatment plan during the study period;\n7. Signed written informed consent.\n\nExclusion Criteria:\n\n1. Uncontrolled epilepsy, history of central nervous system disorders or psychiatric conditions that, in the investigator's judgment, may interfere with the ability to provide informed consent or affect compliance with oral medication.\n2. Prior immunotherapy for any indication or a history of severe hypersensitivity reactions to other monoclonal antibodies.\n3. Clinically significant active cardiac disease, including symptomatic coronary artery disease, congestive heart failure (New York Heart Association \\[NYHA\\] Class II or higher), severe arrhythmias requiring medication, or a history of myocardial infarction within the past 12 months.\n4. Immunosuppressive therapy following organ transplantation.\n5. History of other malignancies within the past 5 years (excluding adequately treated non-melanoma skin cancer or carcinoma in situ).\n6. Severe uncontrolled recurrent infections or other significant uncontrolled comorbidities.\n7. Baseline laboratory values failing to meet the following criteria:Hemoglobin ≥80 g\u002FL; Absolute neutrophil count (ANC) ≥1.5×10\\^9\u002FL; Platelets ≥100×10\\^9\u002FL; ALT\u002FAST ≤2.5×upper limit of normal (ULN); Alkaline phosphatase (ALP) ≤2.5×ULN; Total bilirubin \\\u003C1.5×ULN; Serum creatinine \\\u003C1×ULN\n8. Active gastrointestinal diseases (e.g., gastric\u002Fduodenal ulcers, ulcerative colitis), unresected tumors with active bleeding, or other conditions deemed by the investigator to pose risks of gastrointestinal bleeding or perforation.\n9. Active bleeding or bleeding predisposition.\n10. Pregnancy or lactation.\n11. Hypersensitivity to any component of the investigational drug(s).","75 Years",{"count":138,"type":20},30,[23],"Primary Objectives： Evaluate the complete response rate (CR rate) and safety of short - course radiotherapy combined with ivonesimab (AK112) in patients with pMMR\u002FMSS mid - low rectal cancer.\n\nSecondary Objectives： Evaluate treatment - related toxic reactions, the quality of life, long - term prognosis (local control \\[LC\\], disease - free survival \\[DFS\\] and overall survival \\[OS\\]).\n\nPatients will :\n\nReceive Radiotherapy: Pelvic IMRT or VMAT, DT 25Gy\u002F5Fx. One week after radiotherapy, begin treatment with Ivorsimab (AK112) at a dose of 20mg\u002Fkg by intravenous drip on day 1. One cycle is 21 days, and a total of 6 cycles are to be carried out.\n\nEvaluate the curative effect after 3 cycles of treatment. Patients with progressive disease (PD) will withdraw from the study, and other treatment plans will be adjusted in a timely manner. Patients with CR\u002FPR\u002FSD will continue treatment for another 3 cycles. Conduct a comprehensive assessment after 6 cycles of treatment. Patients who achieve cCR can choose the watch - and - wait approach. For patients who do not achieve cCR, TME surgery is recommended. Decide whether to perform adjuvant chemotherapy based on the postoperative pathological findings.",[142,27,143],"Rectal Cancer","AK112","2025-09-06",{"date":146,"type":32},"2025-09-09",{"date":148,"type":20},"2025-09-01",{"date":150,"type":20},"2028-12-31",{"name":152,"class":39},"Zhejiang Cancer Hospital",{"id":154,"slug":155,"hasResults":11,"nctId":156,"briefTitle":157,"officialTitle":158,"acronym":159,"eligibilityCriteria":160,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":161,"targetDuration":4,"studyType":21,"phases":162,"briefSummary":163,"conditions":164,"keywords":167,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":176,"lastUpdatePostDateStruct":177,"startDateStruct":179,"completionDateStruct":181,"leadSponsor":183,"locationsCount":40},"100535554","optimization-of-radiation-protection-through-genomic-analyses-100535554","NCT06253338","Optimization of Radiation Protection Through Genomic Analyses","Optimization of Radiation Protection Through Genomic Analyses in the Analysis of Changes in Cells of the Hematopoietic System Before and During High Dose External Beam Radiotherapy","ORtogether","Inclusion Criteria:\n\nECOG 0\u002F1 no prior treatment no prior cancer diagnosis thoracic or head and neck cancer\n\nExclusion Criteria:\n\nprior treatment (chemotherapy, radiotherapy, etc.) prior cancer diagnosis",{"count":138,"type":20},[51],"The long-term goal is to define \"signatures\" in the form of genomic changes through sequence analyses of genomic DNA using modern Next Generation Sequencing (NGS) methods, which\n\n1. determine the radiation exposure of humans.\n2. provide information about the exposure (dose).\n3. determine the radiation quality.\n4. predict the repair capacity and radiation resistance of an individual.",[165,166,27],"DNA","Cancer",[165,168,169,170,171,172,173,174,175],"cancer","sequencing technologies","lymphocyte","genomic","loosely ionizing radiation","Linear Energy Transfer","outcome","thoracic radiotherapy","2024-09-25",{"date":178,"type":32},"2024-09-27",{"date":180,"type":32},"2024-06-01",{"date":182,"type":20},"2030-01-15",{"name":184,"class":39},"University Hospital, Essen",{"id":186,"slug":187,"hasResults":11,"nctId":188,"briefTitle":189,"officialTitle":190,"acronym":191,"eligibilityCriteria":192,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":193,"targetDuration":4,"studyType":21,"phases":195,"briefSummary":196,"conditions":197,"keywords":203,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":176,"lastUpdatePostDateStruct":207,"startDateStruct":208,"completionDateStruct":210,"leadSponsor":212,"locationsCount":40},"100532577","prospective-validation-of-adaptive-radiotherapy-art-in-patients-with-head-and-neck-tumors-100532577","NCT06214611","Prospective Validation of Adaptive Radiotherapy (ART) in Patients With Head and Neck Tumors","Adaptive Radiotherapy in the Treatment of Patients With a Histologically Confirmed Malignant Tumor in the Head and Neck Region: Prospective Validation of ART in Patients With HNT (Prospektive Validierung Der ART Bei Patientinnen Und Patienen Mit Kopf-Hals Tumoren,)","ART in HNT","Inclusion Criteria:\n\n1. ECOG 0-1\n2. Histopathology confirmation\n3. Compliance\n4. Tumor in the head and neck region\n5. Indication for radiotherapy\n\nExclusion Criteria:\n\n1\\. Pregnancy",{"count":194,"type":20},50,[51],"Adaptive radiotherapy (ART) includes image-guided radiotherapy (IGRT) and also offers further possibilities for plan adaptation. A particularly high benefit can be expected for patients in whom the clinical target volume (CTV) can show a significant change in shape from fraction to fraction due to anatomical deviations. The shape and position constancy of the CTV during the course of the series is examined in this trial. Dosimetric disadvantages of this type have not been reported so far. The aim of this study is to identify patients who benefit from ART at an early stage and to select them for this method, and then to continue to offer ART to this patient group. If a relevant reduction in the minimum planning target volume (PTV) margins with ART compared to IGRT is demonstrated in this study, patients could be treated with ART.",[198,199,27,200,201,202],"Head and Neck Cancer","Adaptive Radiotherapy","Optimized Treatment","Protection of Organs at Risk","Dysphagia Reduction",[198,199,204,205,206],"Protection of organs at risk","Optimized treatment","Dysphagia reduction",{"date":178,"type":32},{"date":209,"type":32},"2023-11-15",{"date":211,"type":20},"2027-12-15",{"name":184,"class":39},{"id":214,"slug":215,"hasResults":11,"nctId":216,"briefTitle":217,"officialTitle":218,"acronym":4,"eligibilityCriteria":219,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":220,"enrollmentInfo":221,"targetDuration":4,"studyType":73,"phases":4,"briefSummary":222,"conditions":223,"keywords":4,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":226,"lastUpdatePostDateStruct":227,"startDateStruct":229,"completionDateStruct":231,"leadSponsor":233,"locationsCount":235},"100555594","chemoimmunotherapy-plus-residual-lesion-irradiation-for-the-treatment-of-extensive-stage-small-cell-lung-cancer-100555594","NCT06514118","Chemoimmunotherapy Plus Residual Lesion Irradiation for the Treatment of Extensive Stage Small-cell Lung Cancer","Chemoimmunotherapy Plus Ratiotherapy for Extensive Stage Small-cell Lung Cancer","Inclusion Criteria:\n\n\\>= 18 years of age Have an Eastern Cooperative Oncology Group (ECOG) performance status of =\\\u003C 1 at the time of study treatment initiation Histologically or cytologically confirmed diagnosis of small cell lung cancer (SCLC) Patient should have extensive stage disease, defined as, malignant pleural effusion, pulmonary metastases in the contralateral lung, and\u002For the presence of extra-thoracic metastatic disease Must have measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 prior to starting platinum-based systemic chemotherapy Absolute neutrophil count (ANC) \\>= 1.5 x 10\\^9\u002FL Platelets \\>= 100 x 10\\^9\u002FL Hemoglobin \\>= 9 g\u002FdL Serum creatinine =\\\u003C 1.5 x institution upper limit of normal (ULN) and calculated creatinine clearance of at least 15 ml\u002Fmin.\n\nAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) =\\\u003C 3 x upper limit of normal (ULN) (ALT and AST =\\\u003C 5 x ULN is acceptable if liver metastases are present) Total serum bilirubin =\\\u003C 1.5 x ULN. For patients with well documented Gilbert's syndrome, total bilirubin =\\\u003C 3 x ULN with direct bilirubin within normal range.\n\nParticipant must understand the investigational nature of this study and sign an approved written informed consent form prior to receiving any study related procedure.\n\nExclusion Criteria:\n\n* ad major surgery within 14 days prior to starting study drug or has not recovered from major side effects (tumor biopsy is not considered major surgery) resulting from a prior surgery Positive for immunosuppressive disease, acquired immunodeficiency syndrome (AIDS) or other immune depressing diseases. For human immunodeficiency virus (HIV), HVC and HBC-mandatory testing is required prior to enrollment Patient has known hypersensitivity to the components of the study drugs or any analogs History or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the patient's participation for the full duration of the study, or is not in the best interest of the patient to participate, including, but not limited to: Myocardial infarction or arterial or venous thromboembolic events within 6 months prior to baseline or severe or unstable angina, New York Heart Association (NYHA) class III or IV disease. History of documented congestive heart failure (New York Heart Association functional classification III or IV) within 6 months prior to baseline. Poorly controlled arrhythmias","80 Years",{"count":19,"type":20},"This is a phase II trial studies the effect of chemoimmunotherapy sequential residual tumor irradiation in treating patients with extensive stage small cell lung cancer. Even though small cell lung cancer is initially highly responsive to first-line chemotherapy plus PD-L1 inhibitors, treatment resistance inevitably happens. Residual tumor irradiation my prolong drug resistance, and may help prevent the growth and spread of the tumor cells to other parts of the body.",[224,225,27],"Small-cell Lung Cancer","Residual Tumor","2024-07-17",{"date":228,"type":32},"2024-07-23",{"date":230,"type":32},"2024-04-17",{"date":232,"type":20},"2027-03-16",{"name":234,"class":39},"Qingdao Central Hospital",3,{"id":237,"slug":238,"hasResults":11,"nctId":239,"briefTitle":240,"officialTitle":241,"acronym":4,"eligibilityCriteria":242,"healthyVolunteers":11,"sex":111,"minAge":4,"maxAge":4,"enrollmentInfo":243,"targetDuration":4,"studyType":73,"phases":4,"briefSummary":244,"conditions":245,"keywords":247,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":251,"lastUpdatePostDateStruct":252,"startDateStruct":254,"completionDateStruct":256,"leadSponsor":258,"locationsCount":40},"100154584","potential-benefits-of-radiotherapy-in-prone-position-for-breast-cancer-patients-a-planning-study-100154584","NCT01284153","Potential Benefits of Radiotherapy in Prone Position for Breast Cancer Patients: a Planning Study","A Comparison of Three Radiotherapy Techniques for Breast Cancer: a Planning Study","Inclusion Criteria:\n\n* indication for radiotherapy of the breast and \u002For lymph nodes\n\nExclusion Criteria:\n\n* none ( planning study)",{"count":138,"type":20},"This study has the purpose to investigate the benefit of treating breast cancer patients in prone position. This treatment is compared to the standard technique in our center (supine position with or without respiratory gating). The investigators want to compare the doses on the organs at risk (heart and lungs) in the different techniques.",[246,27],"Breast Neoplasms",[248,249,250],"respiratory gating","prone radiotherapy","breast cancer","2024-06-28",{"date":253,"type":32},"2024-07-01",{"date":255,"type":32},"2011-01",{"date":257,"type":20},"2025-10",{"name":259,"class":39},"Universitaire Ziekenhuizen KU Leuven",{"id":261,"slug":262,"hasResults":11,"nctId":263,"briefTitle":264,"officialTitle":265,"acronym":266,"eligibilityCriteria":267,"healthyVolunteers":11,"sex":111,"minAge":17,"maxAge":4,"enrollmentInfo":268,"targetDuration":4,"studyType":21,"phases":269,"briefSummary":270,"conditions":271,"keywords":278,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":287,"lastUpdatePostDateStruct":288,"startDateStruct":290,"completionDateStruct":292,"leadSponsor":294,"locationsCount":40},"100533802","adaptive-radiotherapy-in-patients-with-gynecological-tumors-100533802","NCT06230549","Adaptive Radiotherapy in Patients With Gynecological Tumors","Prospective Randomized Validation of Adaptive Radiotherapy in Patients With Gynecological Tumors and Indication for Radiotherapy","ProART","Inclusion Criteria:\n\nECOG 0-1 confirmation by histophatology MR of the pelvis staging\n\nExclusion Criteria:\n\nRecurrent disease Prior Radiotherapy in pelvic region stage pM1 or cM1",{"count":138,"type":20},[51],"Prospective randomized evaluation of adaptive radiotherapy in the definitive radiotherapy of locally advanced gynecologic carcinoma (e.g. cervical carcinoma, endometrial carcinoma, vaginal carcinoma), in the postoperative situation or first series of external beam radiotherapy and in patients in whom radical surgery or HDR brachytherapy as dose boost is not an option.",[272,199,27,273,274,275,276,277],"Gynecological Tumor","Curative Treatment","Optimization","Adaptive Radiation Therapy","Image Guided Radiotherapy","Cervical Carcinoma",[279,280,281,282,283,284,285,286],"gynecological tumor","adaptive radiotherapy","radiation","curative treatment","optimization","adaptive radiation therapy","image guided radiotherapy","Cervical carcinoma","2024-02-07",{"date":289,"type":32},"2024-02-09",{"date":291,"type":32},"2024-01-15",{"date":293,"type":20},"2026-12-15",{"name":184,"class":39},{"id":296,"slug":297,"hasResults":11,"nctId":298,"briefTitle":299,"officialTitle":300,"acronym":4,"eligibilityCriteria":301,"healthyVolunteers":11,"sex":111,"minAge":17,"maxAge":112,"enrollmentInfo":302,"targetDuration":4,"studyType":21,"phases":303,"briefSummary":304,"conditions":305,"keywords":308,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":311,"lastUpdatePostDateStruct":312,"startDateStruct":314,"completionDateStruct":316,"leadSponsor":318,"locationsCount":320},"100436800","breast-mesh-used-in-two-staged-breast-reconstruction-100436800","NCT04967976","Breast Mesh Used in Two-staged Breast Reconstruction","A Prospective Randomized and Controlled Study of Efficacy and Safety of TiLOOP® Bra Mesh in Patients With Expander-Implant Breast Reconstruction.","Inclusion Criteria:\n\n1. Diagnosed with breast cancer\n2. More than 18 years old\n3. Karnofsky Performance Status (KPS) larger than 80\n4. No clinical or imaging evidence of distant metastasis\n5. BMI \\\u003C 35kg\u002Fm2\n6. Patients with no or mild breast ptosis\n7. No severe deficiency in hematological, cardiovascular system, no immune-deficiency, no severe abnormal liver or kidney function.\n8. Mental Health Patient\n\n   \\-\n\n   Exclusion Criteria:\n\n1\\. Patients with distant metastasis of breast cancer or local recurrence; 2. Past ipsilateral breast\u002Fchest wall radiation; 3. Inflammatory breast cancer, stage IV breast cancer 4. History of severe allergic or specific constitution; 5. Mental illness; 6. Drug\u002Falcohol abuse; 7. Pregnancy, lactation, or impregnated during the trial period; 8. Non-eligible to the study enrollment based on researchers' discretion\n\n\\-",{"count":93,"type":20},[51],"This is the first prospective randomized and controlled study on the efficacy and safety of TiLOOP® Bra mesh in patients with expander-implant breast reconstruction. The investigators hypothesize that incoporating TiLOOP Bra mesh with tissue expanders will reduce the rates of capsular contraction, improve the efficiency of expansion and provide better aesthetic result.",[118,27,306,307],"Breast Reconstruction","Synthetic Mesh",[250,309,281,310],"breast reconstruction","synthetic mesh","2021-07-19",{"date":313,"type":32},"2021-07-20",{"date":315,"type":20},"2021-08-01",{"date":317,"type":20},"2026-08-01",{"name":319,"class":39},"Tianjin Medical University Cancer Institute and Hospital",6,{"id":322,"slug":323,"hasResults":11,"nctId":324,"briefTitle":325,"officialTitle":326,"acronym":327,"eligibilityCriteria":328,"healthyVolunteers":11,"sex":329,"minAge":330,"maxAge":4,"enrollmentInfo":331,"targetDuration":4,"studyType":21,"phases":333,"briefSummary":334,"conditions":335,"keywords":4,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":343,"lastUpdatePostDateStruct":344,"startDateStruct":346,"completionDateStruct":348,"leadSponsor":350,"locationsCount":352},"100356363","salvage-hypofractionated-accelerated-versus-standard-radiotherapy-for-biochemical-failure-after-prostatectomy-100356363","NCT03920033","Salvage Hypofractionated Accelerated Versus Standard Radiotherapy for Biochemical Failure After Prostatectomy","Comparison of Salvage Hypofractionated Accelerated Versus Standard Radiotherapy for Biochemical Recurrence After Radical Prostatectomy (SHARE Trial): a Prospective, Randomized Controlled, Open-label, Multi Center, Superiority Study","SHARE","Inclusion Criteria:\n\n* Pathologically confirmed intermediate- or high-risk prostate cancer\n* Biochemical recurrence after radical prostatectomy (Definition: Serial elevation of PSA over 0.2 ng\u002FmL and \\\u003C=1.0 ng\u002FmL)\n* ECOG performance status 0-1\n* Appropriate values of blood tests within 6 months after enrollment Absolute neutrophil count (ANC) ≥ 1500 cells\u002Fmm3 Platelets ≥ 50,000 cells\u002Fmm3 Hemoglobin ≥ 8.0 g\u002Fdl\n* Appropriate values of kidney function within 6 months after enrollment Creatinine \\\u003C 2.0 ng\u002FdL\n* Appropriate values of liver function within 6 months after enrollment total bilirubin \\\u003C 1.5 X maximum normal value alanine aminotransferase or aspartate aminotransferase \\\u003C 2.5 X maximum normal value\n\nExclusion Criteria:\n\n* Clinically gross recurrent tumor\n* Presence of distant metastasis\n* Presence of pelvic LN metastasis\n* History of pelvic irradiation\n* History of cryotherapy or brachytherapy for prostate cancer\n* Double primary cancer other than skin\u002Fthyroid cancer\n* Combined serious morbidity","MALE","20 Years",{"count":332,"type":20},288,[51],"Patients with a biochemical recurrence after radical prostatectomy for moderate- or high- risk prostate cancer are randomly assigned to hypofractionated, accelerated high dose radiation therapy group (65 Gy, 26 fractions) and a control group of standard treatment group (66 Gy, 33 fractions). The criteria for stratification at randomization include 1) risk groups, 2) androgen deprivation therapy, and 3) PSA before salvage radiation therapy, which affect biochemical recurrence.\n\nIt is expected that hypofractionated, accelerated high dose radiation therapy will have a superiority in terms of biochemical control to conventional radiation therapy, and the present study would like to confirm this. In addition, we aimed to evaluate and compare the toxicity and quality of life index of two radiation therapy regimens.",[336,337,27,338,339,340,341,342],"Prostate Cancer","Biochemical Recurrence","Hypofractionation","Dose Escalation","Survival","Radiation Toxicity","Quality of Life","2021-01-15",{"date":345,"type":32},"2021-01-20",{"date":347,"type":32},"2019-05-01",{"date":349,"type":20},"2027-01-01",{"name":351,"class":39},"Asan Medical Center",2]